Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

[Pharmaceutical follow up of antirretroviral treatment in outpatients].

Moya Y, Bernal F, Rojas E, Barthel E.

Rev Chilena Infectol. 2012 Aug;29(4):412-9. doi: 10.4067/S0716-10182012000400008. Spanish.

2.

[National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].

Panel de expertos de GESIDA y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Spanish.

PMID:
21388714
3.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
4.

[Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2012 Jun;30(6):e1-89. doi: 10.1016/j.eimc.2012.03.006. Epub 2012 May 23. Spanish.

PMID:
22633764
5.

Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.

Palacios R, Santos J, González M, Ruiz J, Valdivielso P, Márquez M, González-Santos P.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):251-3. No abstract available.

PMID:
12394806
6.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
7.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
8.

Apolipoprotein CIII and highly active antiretroviral therapy (HAART)-induced hypertriglyceridemia.

Badiou S, Dupuy AM, Baillat V, Fabre J, Tur MD, Cristol JP, Reynes J.

Clin Lab. 2003;49(1-2):11-3. No abstract available.

PMID:
12593470
9.

[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].

Zhou H, Zheng Y, He Y, Gong G, Chen Z, Liu M, Yin W, Liu C.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Aug;34(8):731-7. Chinese.

10.
11.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
12.

Self-reported adverse reactions among patients initiating antiretroviral therapy in Brazil.

Pádua CA, César CC, Bonolo PF, Acurcio FA, Guimarães MD.

Braz J Infect Dis. 2007 Feb;11(1):20-6.

13.

[Experience at a branch center of the National HIV Protease Inhibitor Registry].

Franco A, Aprea L, Geraci A, Manzillo E, Pizzella T, Simioli F, Mongirulli A, Izzo CM.

Infez Med. 2001 Sep;9(3):170-5. Italian.

14.

HIV disease and advanced age: an increasing therapeutic challenge.

Manfredi R.

Drugs Aging. 2002;19(9):647-69. Review.

PMID:
12381235
15.

Evaluation of adverse events associated with antiretroviral therapy and the relationship to treatment adherence.

Lenzi L, Wiens A, Pontarolo R.

Int J Clin Pharmacol Ther. 2013 Feb;51(2):141-6. doi: 10.5414/CP201818.

PMID:
23253950
16.

Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.

Ware LJ, Jackson AG, Wootton SA, Burdge GC, Morlese JF, Moyle GJ, Jackson AA, Gazzard BG.

Br J Nutr. 2009 Oct;102(7):1038-46. doi: 10.1017/S0007114509338817. Epub 2009 Jun 1.

PMID:
19480729
17.

Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.

Zhou HY, Zheng YH, He Y, Chen Z, Liu M, Yin W, Liu C.

Intervirology. 2010;53(4):240-6. doi: 10.1159/000302762. Epub 2010 Mar 30.

PMID:
20357493
18.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].

Panel de expertos de Gesida y Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2009 Apr;27(4):222-35. doi: 10.1016/j.eimc.2008.11.002. Epub 2009 Feb 26. Spanish. Erratum in: Enferm Infecc Microbiol Clin. 2009 Oct;27(8):491.

PMID:
19246124
19.

Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks.

Zajdenverg R, Podsadecki TJ, Badal-Faesen S, Andrade-Villanueva J, Gathe J, Mingrone H, Fredrick LM, Gaultier IA, Woodward WC, Bernstein BM.

J Acquir Immune Defic Syndr. 2010 Jun;54(2):143-51. doi: 10.1097/QAI.0b013e3181cbd21e.

PMID:
20134330
20.

Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ, Li T, Crauwels H, Rimsky L, Vanveggel S, Williams P, Boven K; ECHO, THRIVE study groups.

AIDS. 2013 Mar 27;27(6):939-50. doi: 10.1097/QAD.0b013e32835cee6e.

PMID:
23211772

Supplemental Content

Support Center